PortalPublikationenDissecting humoral immune responses to an MVA-vectored MERS-...

Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach

Standard

Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach. / Weskamm, Leonie M; Tarnow, Paulina; Harms, Charlotte; Huchon, Melanie; Raadsen, Matthijs P; Friedrich, Monika; Rübenacker, Laura; Grüttner, Cordula; Garcia, Mariana G; Koch, Till; Becker, Stephan; Sutter, Gerd; Lhomme, Edouard; Haagmans, Bart L; Fathi, Anahita; Blois, Sandra M; Dahlke, Christine; Richert, Laura; Addo, Marylyn M; MVA-MERS-S-CEF study group.

in: ISCIENCE, Jahrgang 27, Nr. 8, 16.08.2024, S. 110470.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Weskamm, LM, Tarnow, P, Harms, C, Huchon, M, Raadsen, MP, Friedrich, M, Rübenacker, L, Grüttner, C, Garcia, MG, Koch, T, Becker, S, Sutter, G, Lhomme, E, Haagmans, BL, Fathi, A, Blois, SM, Dahlke, C, Richert, L, Addo, MM & MVA-MERS-S-CEF study group 2024, 'Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach', ISCIENCE, Jg. 27, Nr. 8, S. 110470. https://doi.org/10.1016/j.isci.2024.110470

APA

Weskamm, L. M., Tarnow, P., Harms, C., Huchon, M., Raadsen, M. P., Friedrich, M., Rübenacker, L., Grüttner, C., Garcia, M. G., Koch, T., Becker, S., Sutter, G., Lhomme, E., Haagmans, B. L., Fathi, A., Blois, S. M., Dahlke, C., Richert, L., Addo, M. M., & MVA-MERS-S-CEF study group (2024). Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach. ISCIENCE, 27(8), 110470. https://doi.org/10.1016/j.isci.2024.110470

Vancouver

Weskamm LM, Tarnow P, Harms C, Huchon M, Raadsen MP, Friedrich M et al. Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach. ISCIENCE. 2024 Aug 16;27(8):110470. https://doi.org/10.1016/j.isci.2024.110470

Bibtex

@article{d5839b0202b44208a74139becb57422b,
title = "Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach",
abstract = "Besides neutralizing antibodies, which are considered an important measure for vaccine immunogenicity, Fc-mediated antibody functions can contribute to antibody-mediated protection. They are strongly influenced by structural antibody properties such as subclass and Fc glycan composition. We here applied a systems serology approach to dissect humoral immune responses induced by MVA-MERS-S, an MVA-vectored vaccine against the Middle East respiratory syndrome coronavirus (MERS-CoV). Building on preceding studies reporting the safety and immunogenicity of MVA-MERS-S, our study highlights the potential of a late boost, administered one year after prime, to enhance both neutralizing and Fc-mediated antibody functionality compared to the primary vaccination series. Distinct characteristics were observed for antibodies specific to the MERS-CoV spike protein S1 and S2 subunits, regarding subclass and glycan compositions as well as Fc functionality. These findings highlight the benefit of a late homologous booster vaccination with MVA-MERS-S and may be of interest for the design of future coronavirus vaccines.",
author = "Weskamm, {Leonie M} and Paulina Tarnow and Charlotte Harms and Melanie Huchon and Raadsen, {Matthijs P} and Monika Friedrich and Laura R{\"u}benacker and Cordula Gr{\"u}ttner and Garcia, {Mariana G} and Till Koch and Stephan Becker and Gerd Sutter and Edouard Lhomme and Haagmans, {Bart L} and Anahita Fathi and Blois, {Sandra M} and Christine Dahlke and Laura Richert and Addo, {Marylyn M} and {MVA-MERS-S-CEF study group}",
note = "{\textcopyright} 2024 The Author(s).",
year = "2024",
month = aug,
day = "16",
doi = "10.1016/j.isci.2024.110470",
language = "English",
volume = "27",
pages = "110470",
journal = "ISCIENCE",
issn = "2589-0042",
publisher = "Elsevier Inc.",
number = "8",

}

RIS

TY - JOUR

T1 - Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach

AU - Weskamm, Leonie M

AU - Tarnow, Paulina

AU - Harms, Charlotte

AU - Huchon, Melanie

AU - Raadsen, Matthijs P

AU - Friedrich, Monika

AU - Rübenacker, Laura

AU - Grüttner, Cordula

AU - Garcia, Mariana G

AU - Koch, Till

AU - Becker, Stephan

AU - Sutter, Gerd

AU - Lhomme, Edouard

AU - Haagmans, Bart L

AU - Fathi, Anahita

AU - Blois, Sandra M

AU - Dahlke, Christine

AU - Richert, Laura

AU - Addo, Marylyn M

AU - MVA-MERS-S-CEF study group

N1 - © 2024 The Author(s).

PY - 2024/8/16

Y1 - 2024/8/16

N2 - Besides neutralizing antibodies, which are considered an important measure for vaccine immunogenicity, Fc-mediated antibody functions can contribute to antibody-mediated protection. They are strongly influenced by structural antibody properties such as subclass and Fc glycan composition. We here applied a systems serology approach to dissect humoral immune responses induced by MVA-MERS-S, an MVA-vectored vaccine against the Middle East respiratory syndrome coronavirus (MERS-CoV). Building on preceding studies reporting the safety and immunogenicity of MVA-MERS-S, our study highlights the potential of a late boost, administered one year after prime, to enhance both neutralizing and Fc-mediated antibody functionality compared to the primary vaccination series. Distinct characteristics were observed for antibodies specific to the MERS-CoV spike protein S1 and S2 subunits, regarding subclass and glycan compositions as well as Fc functionality. These findings highlight the benefit of a late homologous booster vaccination with MVA-MERS-S and may be of interest for the design of future coronavirus vaccines.

AB - Besides neutralizing antibodies, which are considered an important measure for vaccine immunogenicity, Fc-mediated antibody functions can contribute to antibody-mediated protection. They are strongly influenced by structural antibody properties such as subclass and Fc glycan composition. We here applied a systems serology approach to dissect humoral immune responses induced by MVA-MERS-S, an MVA-vectored vaccine against the Middle East respiratory syndrome coronavirus (MERS-CoV). Building on preceding studies reporting the safety and immunogenicity of MVA-MERS-S, our study highlights the potential of a late boost, administered one year after prime, to enhance both neutralizing and Fc-mediated antibody functionality compared to the primary vaccination series. Distinct characteristics were observed for antibodies specific to the MERS-CoV spike protein S1 and S2 subunits, regarding subclass and glycan compositions as well as Fc functionality. These findings highlight the benefit of a late homologous booster vaccination with MVA-MERS-S and may be of interest for the design of future coronavirus vaccines.

U2 - 10.1016/j.isci.2024.110470

DO - 10.1016/j.isci.2024.110470

M3 - SCORING: Journal article

C2 - 39148710

VL - 27

SP - 110470

JO - ISCIENCE

JF - ISCIENCE

SN - 2589-0042

IS - 8

ER -